The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with ...
On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, ...
Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the ...
Total abortion bans effective by early 2023 were associated with a 1.57% monthly birth-rate increase, approximately 1,210 ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.
Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results